<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03232710</url>
  </required_header>
  <id_info>
    <org_study_id>KH716-E01-CRP-1.1</org_study_id>
    <nct_id>NCT03232710</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition</brief_title>
  <official_title>A Single-dose, Two-treatment, Two-sequence, Two-period, Two Way Crossover Bioequivalence Study of Bosiqing Aripiprazole Orally Disintegrating Tablets and ABILIFY Under Fasting/Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chengdu Kanghong Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chengdu Kanghong Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate and extent of absorption of Aripiprazole Orally disintegrating tablets 10&#xD;
      mg of Chengdu Kanghong Pharmaceutical Group Co.,Ltd, China and ABILIFY (Aripiprazole) 10 mg&#xD;
      orodispersible tablets of Otsuka Pharmaceutical Europe Ltd. in healthy, adult, human subjects&#xD;
      under fasting/fed condition as well as to monitor the safety and tolerability of subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Cmax</measure>
    <time_frame>day 54</time_frame>
    <description>Bioequivalence based on Peak Plasma Concentration (Cmax) under fasting and fed condition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: AUC</measure>
    <time_frame>day 54</time_frame>
    <description>Bioequivalence based on Area under the plasma concentration versus time curves (AUC) under fasting and fed condition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to day 54</time_frame>
    <description>To observe the type, incidence and severity of adverse events in the study.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>pilot study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 1 (under fasting condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 (under fasting condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3 (under fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4 (under fed condition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosiqing</intervention_name>
    <description>Aripiprazole Orally disintegrating tablets 10mg</description>
    <arm_group_label>group 1 (under fasting condition)</arm_group_label>
    <arm_group_label>group 2 (under fasting condition)</arm_group_label>
    <arm_group_label>group 3 (under fed condition)</arm_group_label>
    <arm_group_label>group 4 (under fed condition)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abilify</intervention_name>
    <description>Aripiprazol orodispersible tablets 10mg</description>
    <arm_group_label>group 1 (under fasting condition)</arm_group_label>
    <arm_group_label>group 2 (under fasting condition)</arm_group_label>
    <arm_group_label>group 3 (under fed condition)</arm_group_label>
    <arm_group_label>group 4 (under fed condition)</arm_group_label>
    <arm_group_label>pilot study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects willing to adhere to the protocol requirements and to provide written&#xD;
             informed consent.&#xD;
&#xD;
          2. Subjects aged between 45 and 65 years，healthy male and non-pregnant, non breast&#xD;
             feeding female.&#xD;
&#xD;
          3. Subjects' weight within clinically acceptable normal range according to normal values&#xD;
             for Body Mass Index (19.00 to 26.00 kg/m2) with minimum of 50 kg weight for male, and&#xD;
             minimum of 45 kg weight for female.&#xD;
&#xD;
          4. No medical history of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital&#xD;
             or psychiatric disease or disorder.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1)Subjects with family history of muscular dystonia or the subject has had the drug&#xD;
             source dystonia.&#xD;
&#xD;
             2）Subject with history of a asthma. 3）Subject with any (acute or chronic) history of&#xD;
             mental illness or have family history of mental illness.&#xD;
&#xD;
             4）Subject have alzheimer's or alzheimer's disease. 5）Subject was hospitalized within&#xD;
             60 days prior to the first dose of the study drug 6）Subject smoking more than five&#xD;
             cigarettes within 1 month prior to the first dose study drug.&#xD;
&#xD;
             7）History or presence of significant easy bruising or bleeding 8）History or presence&#xD;
             of drug abuse. 9）History of allergic reactions. 10）History or presence of taking&#xD;
             psychotropic drugs。 11）Subjects having positive urine screen for drugs of abuse&#xD;
             including Methamphetamine, MDMA, ketamine, morphine, heroin.&#xD;
&#xD;
             12）Any treatment which could bring about induction or inhibition of hepatic microsomal&#xD;
             enzyme system within 3 weeks prior to Period 01 dosing.&#xD;
&#xD;
             13）Consumption of hypericum perforatum containing products and grapefruit or&#xD;
             grapefruit juice from 72 hours prior admission to 3 days after trail end.&#xD;
&#xD;
             14）Subject involved other clinical trials of drugs within 3 months prior to period 01&#xD;
             dosing.&#xD;
&#xD;
             15）Subject with abnormal laboratory tests and diagnosed by physicians as clinically&#xD;
             significant 17）Abnormal vital signs test for any one or more:&#xD;
&#xD;
        Abnormal blood pressure:&#xD;
&#xD;
          -  Systolic pressure is lower than 80mmHg and/or diastolic pressure down to 40mmHg in&#xD;
             sitting position.&#xD;
&#xD;
          -  Systolic pressure is higher than 140mmHg and/or diastolic pressure higher than 90mmHg&#xD;
             in sitting position.&#xD;
&#xD;
        Abnormal cardiac rate:&#xD;
&#xD;
          -  cardiac rate lower than 50&#xD;
&#xD;
          -  cardiac rate higher than 50 18）Blood alcohol test values≥10mg/dL 19）Volunteer who have&#xD;
             donated blood components within 2 weeks prior to the first dose or donated blood (more&#xD;
             than 200 ml within 4 weeks; more than 400 ml within 60 days) prior to the first dose;&#xD;
             Volunteer who plan to donate blood during the study or 4 weeks after study; Volunteer&#xD;
             who lost blood (more than 50ml within 7days or more than 400ml within 30 days) for&#xD;
             surgery.&#xD;
&#xD;
             20）Subjects not willing to follow approved birth control methods for the duration of&#xD;
             the study 21）ubjects having positive Serum β-hCG test. 22）Subjects plan to donate&#xD;
             sperm during study period or 30 days after study 23）Hamilton depression Rating Scale (&#xD;
             17 ) score above 7 points. 24）History of blood phobia. Subjects whom the investigator&#xD;
             deems necessary to exclude.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiang Jin</last_name>
    <phone>+83-13880932568</phone>
    <email>11679295@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Jin</last_name>
      <email>11679295@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>July 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

